Treatment of giardiasis

Area of Science:

• Infectious Diseases
• Pharmacology
• Parasitology

Background:

• Giardia lamblia is a prevalent intestinal parasite causing global diarrheal illness.
• Limited therapeutic agents are available for giardiasis treatment.
• Understanding drug efficacy and safety is crucial for managing this common infection.

Purpose of the Study:

• To review and compare various drug classes used for Giardia lamblia treatment.
• To detail the mechanism of action, efficacy, and side effects of available therapies.
• To provide treatment recommendations for different clinical scenarios.

Main Methods:

• Review of existing literature on pharmacotherapy for giardiasis.
• Analysis of in vitro and clinical data on drug effectiveness.
• Evaluation of drug side effects, contraindications, and resistance patterns.

Main Results:

• Nitroimidazoles (metronidazole, tinidazole, ornidazole) demonstrate high efficacy, with single doses of tinidazole/ornidazole and a 5-7 day course of metronidazole achieving over 90% cure rates.
• Quinacrine is effective but may cause intolerance, particularly in children.
• Furazolidone is an alternative requiring frequent dosing; paromomycin is a safer option in early pregnancy but less consistently effective.

Conclusions:

• Nitroimidazole drugs are the preferred first-line treatment for Giardia lamblia infections due to their high efficacy and established safety profiles.
• Combination therapy with a nitroimidazole and quinacrine can be effective for treating resistant infections.
• Treatment choices should consider clinical situation, patient factors (e.g., pregnancy, age), and drug-specific efficacy and tolerability.